Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 11,176 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers

NCT00990990
View directory record Official record
Conditions
Tuberculosis
Interventions
PNU-100480, Placebo, Linezolid
Drug
Lead sponsor
Sequella, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Nov 4, 2026, 2:37 AM EST
Recruiting Phase 1 Interventional

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

NCT05932862
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
XL309, Olaparib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
16
States / cities
Fountain Valley, California • Jacksonville, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Nov 4, 2026, 2:37 AM EST
Completed Phase 1 Interventional

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

NCT03008161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NPT088, Placebo
Drug
Lead sponsor
Proclara Biosciences, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
Costa Mesa, California • Fullerton, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Nov 4, 2026, 2:37 AM EST
Completed Phase 2Phase 3 Interventional Results available

PRecision Interventions for SMoking in the SCCS

NCT03521141
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Nicotine patch, Varenicline, Nicotine metabolism, Genetically-informed lung cancer risk score, NCI "Clearing the Air"
Drug · Genetic · Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Nov 4, 2026, 2:37 AM EST
Terminated Phase 1 Interventional Results available

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982
View directory record Official record
Conditions
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer
Interventions
ADCT-301, Pembrolizumab
Drug · Biological
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Palo Alto, California • New Haven, Connecticut • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Nov 4, 2026, 2:37 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Assessment of Paclitaxel-Induced Neuropathy

NCT01953159
View directory record Official record
Conditions
Cancer, Breast Cancer, Ovarian Cancer
Interventions
Blood Collection, Patient Questionnaires
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Nov 4, 2026, 2:37 AM EST
Terminated Phase 1 Interventional

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627
View directory record Official record
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions
Nivolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Nov 4, 2026, 2:37 AM EST
Recruiting No phase listed Observational

Androgens and NAFLD Longitudinal Cohort Study

NCT06124261
View directory record Official record
Conditions
PCOS, NAFLD, NASH
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
San Francisco, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 4, 2026, 2:37 AM EST
Completed Phase 1 Interventional

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

NCT01656642
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Atezolizumab, Cobimetinib, Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Nov 4, 2026, 2:37 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

NCT05824091
View directory record Official record
Conditions
Tuberculosis
Interventions
MK-7762 (TBD09), Placebo
Drug · Other
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
19 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 4, 2026, 2:37 AM EST
Terminated Phase 1Phase 2 Interventional Results available

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

NCT04913220
View directory record Official record
Conditions
Malignant Melanoma, Squamous Cell Carcinoma of Skin
Interventions
THOR-707, Cemiplimab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 4, 2026, 2:37 AM EST
Terminated Phase 1Phase 2 Interventional Results available

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

NCT02452424
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
Interventions
PLX3397, Pembrolizumab
Drug · Biological
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Nov 4, 2026, 2:37 AM EST
Recruiting Phase 3 Interventional

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

NCT05821959
View directory record Official record
Conditions
Sensorineural Hearing Loss, Bilateral
Interventions
AAVAnc80-hOTOF via Akouos Delivery Device, AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
Combination Product
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
San Francisco, California • Iowa City, Iowa • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 4, 2026, 2:37 AM EST
Completed Phase 1 Interventional

A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors

NCT01358903
View directory record Official record
Conditions
Neoplasms
Interventions
RO5429083
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 4, 2026, 2:37 AM EST
Completed Not applicable Interventional

Decreasing Agitation in Patients With Dementia Through the Use of Weighted Blankets

NCT03643991
View directory record Official record
Conditions
Dementia
Interventions
Weighted Blanket
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Nov 4, 2026, 2:37 AM EST
Completed Phase 1 Interventional

Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors

NCT01111097
View directory record Official record
Conditions
Brain Tumor, Glioblastoma
Interventions
Dichloroacetate
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Nov 4, 2026, 2:37 AM EST
Terminated Phase 1 Interventional Results available

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

NCT01483183
View directory record Official record
Conditions
Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Interventions
OPC-108459, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Hollywood, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Nov 4, 2026, 2:37 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Two Sessions of Coach-Delivered Core Transformation for Distress and Well-Being

NCT07879196
View directory record Official record
Conditions
Psychological Distress, Psychological Well-being
Interventions
Core Transformation Process
Behavioral
Lead sponsor
Andreas NLP (Legal Entity - Real People Press)
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 2:37 AM EST
Completed No phase listed Observational

Global Anticoagulant Registry in the Field

NCT01090362
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Thrombosis Research Institute
Other
Eligibility
18 Years and older
Enrollment
57,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Nov 4, 2026, 2:37 AM EST
Recruiting Phase 2 Interventional

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

NCT05894083
View directory record Official record
Conditions
Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx
Interventions
Surgery, Chemoradiation, Observation, Post-operative radiation
Procedure · Combination Product · Other + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Nov 4, 2026, 2:37 AM EST
Active, not recruiting Phase 1 Interventional

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

NCT04420754
View directory record Official record
Conditions
Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer
Interventions
AIC100 CAR T Cells
Biological
Lead sponsor
AffyImmune Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 4, 2026, 2:37 AM EST
Completed No phase listed Observational

Follow up Study of Diaphragm Pacing for Patients With High Tetraplegia

NCT01815554
View directory record Official record
Conditions
Tetraplegia, Spinal Cord Injury
Interventions
Not listed
Lead sponsor
Craig Hospital
Other
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Nov 4, 2026, 2:37 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants

NCT06640920
View directory record Official record
Conditions
Healthy
Interventions
Cohort A, Cohort B, Cohort C, Cohort D
Biological
Lead sponsor
Uniquity One (UNI)
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Nov 4, 2026, 2:37 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

NCT03574779
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, TSR-042, Bevacizumab, Carboplatin, Paclitaxel
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Nov 4, 2026, 2:37 AM EST